Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Myofibroblasts produce the fibrous scar in hepatic fibrosis. In the carbon tetrachloride (CCl(4)) model of liver fibrosis, quiescent hepatic stellate cells (HSC) are activated to become myofibroblasts. When the underlying etiological agent is removed, clinical and experimental fibrosis undergoes a remarkable regression with complete disappearance of these myofibroblasts. Although some myofibroblasts apoptose, it is unknown whether other myofibroblasts may revert to an inactive phenotype during regression of fibrosis. We elucidated the fate of HSCs/myofibroblasts during recovery from CCl(4)- and alcohol-induced liver fibrosis using Cre-LoxP-based genetic labeling of myofibroblasts. Here we demonstrate that half of the myofibroblasts escape apoptosis during regression of liver fibrosis, down-regulate fibrogenic genes, and acquire a phenotype similar to, but distinct from, quiescent HSCs in their ability to more rapidly reactivate into myofibroblasts in response to fibrogenic stimuli and strongly contribute to liver fibrosis. Inactivation of HSCs was associated with up-regulation of the anti-apoptotic genes Hspa1a/b, which participate in the survival of HSCs in culture and in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, restored RSPO3 expression during HSC deactivation52,53 or by therapeutic interventions might help to regain hepatocyte functions.”
From Hepatic stellate cells control liver zonation, size and functions via R-spondin 3 (2025) · cites this paper as [52]
In the citing paper
“Animal models reinforce the capacity of the injured liver to regress fibrosis and provide important platform for dissecting underlying mechanisms, although it should be noted that fibrosis in mice regresses incredibly rapidly, which may be in part attributed to the short duration of models (weeks to months in mice vs. years to decades in humans) and initiation of fibrosis at relatively young age (”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [262]
In the citing paper
“Fibroblast activation also involves increased activity of key glycolytic enzymes, such as hexokinase 2 and lactate dehydrogenase (LDH)47, which in turn increase cell proliferation47 and collagen synthesis48.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [47]
In the citing paper
“During enhanced glycolysis, increased amounts of pyruvate are converted to acetyl-CoA in the mitochondrial matrix47 before entering the citric acid cycle. This yields intermediate metabolites, such as succinate, which promote fibrosis49.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [47]
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Self-citationSenescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Self-citationBataller, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524282c1 · Cited by 1,472
Iredale, J. P., Benyon, R. C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., Hovell, C., & Arthur, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1018 · Cited by 1,075 · cited 8×
“Myofibroblasts are aSMA collagen type I cells that are absent from the normal uninjured liver, rapidly emerge infibrotic liver to produce thefibrous scar, and completely disappear with regression of liver fibrosis (1, 2).”
BackgroundInfluentialThe role of matrix stiffness in regulating cell behavior†
Wells, R. G. (2008) · Hepatology · doi:10.1002/hep.22193 · Cited by 1,059
Hepatic lipocytes: the principal collagen-producing cells of normal rat liver.
Friedman, S. L., Roll, F. J., Boyles, J., & Bissell, D. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.24.8681 · Cited by 859
Lee, K. S., Buck, M., Houglum, K., & Chojkier, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118304 · Cited by 539
Ito Cells Are Liver-Resident Antigen-Presenting Cells for Activating T Cell Responses
Winau, F., Hegasy, G., Weiskirchen, R., Weber, S., Cassan, C., Sieling, P. A., Modlin, R. L., Liblau, R. S., Gressner, A. M., & Kaufmann, S. H. E. (2007) · Immunity · doi:10.1016/j.immuni.2006.11.011 · Cited by 410
Lee, C. G., Cho, S. J., Kang, M. J., Chapoval, S. P., Lee, P. J., Noble, P. W., Yehualaeshet, T., Lu, B., Flavell, R. A., Milbrandt, J., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040104 · Cited by 369
Cited by
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Self-citationTurning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,879
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
Hepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., Pradere, J.-P., & Schwabe, R. F. (2013) · Nature Communications · doi:10.1038/ncomms3823 · Cited by 1,443
Liver fibrosis and repair: Immune regulation of wound healing in a solid organ
Pellicoro, A., Ramachandran, P., Iredale, J. P., & Fallowfield, J. A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3623 · Cited by 1,310
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
Self-citationDiversity and biology of cancer-associated fibroblasts
Biffi, G., & Tuveson, D. A. (2021) · Physiological Reviews · doi:10.1152/physrev.00048.2019 · Cited by 1,265
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
“Fibrosis regression is associated with inactivation or apoptosis of HSCs and myofibroblasts [56,232].”
BackgroundMouse model of chronic and binge ethanol feeding (the NIAAA model)
Bertola, A., Mathews, S., Ki, S. H., Wang, H., & Gao, B. (2013) · Nature Protocols · doi:10.1038/nprot.2013.032 · Cited by 1,213
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Parola, M., & Pinzani, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.09.002 · Cited by 1,160
Sherman, M. H., Yu, R. T., Engle, D. D., Ding, N., Atkins, A. R., Tiriac, H., Collisson, E. A., Connor, F., Van Dyke, T., Kozlov, S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.007 · Cited by 1,158
Pathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894
Roles for chemokines in liver disease
Marra, F., & Tacke, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.043 · Cited by 829
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
Hepatic stellate cells in liver development, regeneration, and cancer
Yin, C., Evason, K. J., Asahina, K., & Stainier, D. Y. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66369 · Cited by 719
Fibroblast and myofibroblast activation in normal tissue repair and fibrosis
Younesi, F. S., Miller, A. E., Barker, T. H., Rossi, F. M. V., & Hinz, B. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00716-0 · Cited by 681
Fibrosis and cancer: A strained relationship
Piersma, B., Hayward, M.-K., & Weaver, V. M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188356 · Cited by 680
Hepatic fibrosis: concept to treatment
Trautwein, C., Friedman, S. L., Schuppan, D., & Pinzani, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.039 · Cited by 677
“HSCs, following their activation to myofibroblasts, can revert to an inactivated, albeit not fully quiescent, state [21].”
BackgroundTherapy for Fibrotic Diseases: Nearing the Starting Line
Friedman, S. L., Sheppard, D., Duffield, J. S., & Violette, S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004700 · Cited by 655
“Nevertheless, even such “deactivated” cells are primed to more easily reactivate upon recurrent tissue injury (42).”
BackgroundCellular and molecular mechanisms in kidney fibrosis
Duffield, J. S. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72267 · Cited by 629
Host Responses in Tissue Repair and Fibrosis
Duffield, J. S., Lupher, M., Thannickal, V. J., & Wynn, T. A. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163930 · Cited by 624
Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases
Hinz, B., & Lagares, D. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0324-5 · Cited by 614
Pradere, J.-P., Kluwe, J., De Minicis, S., Jiao, J.-J., Gwak, G.-Y., Dapito, D. H., Jang, M.-K., Guenther, N. D., Mederacke, I., Friedman, R., et al. (2013) · Hepatology · doi:10.1002/hep.26429 · Cited by 613
Evolving therapies for liver fibrosis
Schuppan, D., & Kim, Y. O. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66028 · Cited by 595
Preparing the ground for tissue regeneration: from mechanism to therapy
Forbes, S. J., & Rosenthal, N. (2014) · Nature Medicine · doi:10.1038/nm.3653 · Cited by 585
High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers
Mederacke, I., Dapito, D. H., Affò, S., Uchinami, H., & Schwabe, R. F. (2015) · Nature Protocols · doi:10.1038/nprot.2015.017 · Cited by 549
Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications
Weiskirchen, R., Weiskirchen, S., & Tacke, F. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.003 · Cited by 538
Origin of myofibroblasts in the fibrotic liver in mice
Iwaisako, K., Jiang, C., Zhang, M., Cong, M., Moore-Morris, T. J., Park, T. J., Liu, X., Xu, J., Wang, P., Paik, Y.-H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400062111 · Cited by 535
Self-citationDeactivation of Hepatic Stellate Cells During Liver Fibrosis Resolution in Mice
Troeger, J. S., Mederacke, I., Gwak, G., Dapito, D. H., Mu, X., Hsu, C. C., Pradere, J., Friedman, R. A., & Schwabe, R. F. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.036 · Cited by 515
Liver sinusoidal endothelial cells in hepatic fibrosis
DeLeve, L. D. (2015) · Hepatology · doi:10.1002/hep.27376 · Cited by 482
“In vivo studies have suggested that activated HSCs do not revert to full quiescence upon regression of fibrosis, but that HSCs that develop a quiescent phenotype after regression of fibrosis are poised to rapidly reactivate when challenged with a fibrotic stimulus.(47) These HSCs have been termed inactivated HSCs.”
BackgroundDeterminants of Fibrosis Progression and Regression in NASH
Schuppan, D., Surabattula, R., & Wang, X. Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.012 · Cited by 479
Intestinal fungi contribute to development of alcoholic liver disease
Yang, A.-M., Inamine, T., Hochrath, K., Chen, P., Wang, L., Llorente, C., Bluemel, S., Hartmann, P., Xu, J., Koyama, Y., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90562 · Cited by 464
Self-citationZhou, Y., Huang, X., Hecker, L., Kurundkar, D., Kurundkar, A., Liu, H., Jin, T.-H., Desai, L., Bernard, K., & Thannickal, V. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66700 · Cited by 455
Mechanisms of liver fibrosis and its role in liver cancer
Dhar, D., Baglieri, J., Kisseleva, T., & Brenner, D. A. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370219898141 · Cited by 429
Self-citationThe Power of Plasticity—Metabolic Regulation of Hepatic Stellate Cells
Trivedi, P., Wang, S., & Friedman, S. L. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.026 · Cited by 427
Hinz, B. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2015.07.009 · Cited by 424
Activated fibroblasts in cancer: Perspectives and challenges
Caligiuri, G., & Tuveson, D. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.015 · Cited by 424
Charrier, E. E., Pogoda, K., Wells, R. G., & Janmey, P. A. (2018) · Nature Communications · doi:10.1038/s41467-018-02906-9 · Cited by 415
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Musso, G., Cassader, M., & Gambino, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.3 · Cited by 412
Xie, G., Wang, X., Wang, L., Wang, L., Atkinson, R. D., Kanel, G. C., Gaarde, W. A., & DeLeve, L. D. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.017 · Cited by 410
Adverse outcome pathways: opportunities, limitations and open questions
Leist, M., Ghallab, A., Graepel, R., Marchan, R., Hassan, R., Bennekou, S. H., Limonciel, A., Vinken, M., Schildknecht, S., Waldmann, T., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2045-3 · Cited by 394
Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis
Fabregat, I., & Caballero-Díaz, D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00357 · Cited by 351
Experimental models of liver fibrosis
Crespo Yanguas, S., Cogliati, B., Willebrords, J., Maes, M., Colle, I., van den Bossche, B., de Oliveira, C. P. M. S., Andraus, W., Alves, V. A., Leclercq, I., et al. (2016) · Archives of Toxicology · doi:10.1007/s00204-015-1543-4 · Cited by 350
Myofibroblasts: Trust your heart and let fate decide
Davis, J., & Molkentin, J. D. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.10.019 · Cited by 345
Jun, J.-I., & Lau, L. F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93563 · Cited by 345
Hepatic inflammation and progressive liver fibrosis in chronic liver disease
Czaja, A. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2515 · Cited by 342
Origin of myofibroblasts and cellular events triggering fibrosis
Mack, M., & Yanagita, M. (2015) · Kidney International · doi:10.1038/ki.2014.287 · Cited by 342
Liedtke, C., Luedde, T., Sauerbruch, T., Scholten, D., Streetz, K., Tacke, F., Tolba, R., Trautwein, C., Trebicka, J., & Weiskirchen, R. (2013) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-6-19 · Cited by 335
Self-citationTschumperlin, D. J., Ligresti, G., Hilscher, M. B., & Shah, V. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93561 · Cited by 330
Bu, L., Baba, H., Yoshida, N., Miyake, K., Yasuda, T., Uchihara, T., Tan, P., & Ishimoto, T. (2019) · Oncogene · doi:10.1038/s41388-019-0765-y · Cited by 329
The myofibroblast, a key cell in normal and pathological tissue repair
Darby, I. A., Zakuan, N., Billet, F., & Desmoulière, A. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2110-0 · Cited by 328
Hepatic stellate cells in physiology and pathology
Kamm, D. R., & McCommis, K. S. (2022) · The Journal of Physiology · doi:10.1113/jp281061 · Cited by 325
Liver regeneration and inflammation: from fundamental science to clinical applications
Campana, L., Esser, H., Huch, M., & Forbes, S. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00373-7 · Cited by 307
Recent advancement of molecular mechanisms of liver fibrosis
Seki, E., & Brenner, D. A. (2015) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.245 · Cited by 300
Self-citationRegeneration of Dermis: Scarring and Cells Involved
Rippa, A. L., Kalabusheva, E. P., & Vorotelyak, E. A. (2019) · Cells · doi:10.3390/cells8060607 · Cited by 294
Pakshir, P., Noskovicova, N., Lodyga, M., Son, D. O., Schuster, R., Goodwin, A., Karvonen, H., & Hinz, B. (2020) · Journal of Cell Science · doi:10.1242/jcs.227900 · Cited by 293
The myofibroblast in wound healing and fibrosis: answered and unanswered questions
Bochaton-Piallat, M.-L., Gabbiani, G., & Hinz, B. (2016) · F1000Research · doi:10.12688/f1000research.8190.1 · Cited by 293
Pathological mechanisms and therapeutic outlooks for arthrofibrosis
Usher, K. M., Zhu, S., Mavropalias, G., Carrino, J. A., Zhao, J., & Xu, J. (2019) · Bone Research · doi:10.1038/s41413-019-0047-x · Cited by 285
Extracellular matrix in lung development, homeostasis and disease
Zhou, Y., Horowitz, J. C., Naba, A., Ambalavanan, N., Atabai, K., Balestrini, J., Bitterman, P. B., Corley, R. A., Ding, B.-S., Engler, A. J., et al. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.03.005 · Cited by 284
D'Urso, M., & Kurniawan, N. A. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.609653 · Cited by 280
Widjaja, A. A., Singh, B. K., Adami, E., Viswanathan, S., Dong, J., D’Agostino, G. A., Ng, B., Lim, W. W., Tan, J., Paleja, B. S., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.05.002 · Cited by 278
Hedgehog signaling in the liver
Omenetti, A., Choi, S., Michelotti, G., & Diehl, A. M. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.10.003 · Cited by 277
Reversibility of liver fibrosis
Sun, M., & Kisseleva, T. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.06.015 · Cited by 274
Self-citationCellular and Molecular Mechanisms Underlying Liver Fibrosis Regression
Caligiuri, A., Gentilini, A., Pastore, M., Gitto, S., & Marra, F. (2021) · Cells · doi:10.3390/cells10102759 · Cited by 270
Extracellular matrix degradation in liver fibrosis: Biochemistry and regulation
Iredale, J. P., Thompson, A., & Henderson, N. C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.002 · Cited by 269
Iron and liver fibrosis: Mechanistic and clinical aspects
Mehta, K. J., Farnaud, S. J., & Sharp, P. A. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i5.521 · Cited by 269
Novel insights into the function and dynamics of extracellular matrix in liver fibrosis
Karsdal, M. A., Manon-Jensen, T., Genovese, F., Kristensen, J. H., Nielsen, M. J., Sand, J. M. B., Hansen, N.-U. B., Bay-Jensen, A.-C., Bager, C. L., Krag, A., et al. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00447.2014 · Cited by 263
Kim, K.-H., Chen, C.-C., Monzon, R. I., & Lau, L. F. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00049-13 · Cited by 261
“notype (9, 10) or enter a senescence state (11), leading to the”
BackgroundLiver fibrosis: Pathophysiology and clinical implications
Berumen, J., Baglieri, J., Kisseleva, T., & Mekeel, K. (2021) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1499 · Cited by 259
Self-citationWeiskirchen, R., & Tacke, F. (2014) · PubMed · doi:10.3978/j.issn.2304-3881.2014.11.03 · Cited by 256
Defining the Cardiac Fibroblast
Ivey, M. J., & Tallquist, M. D. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-1003 · Cited by 255
Cellular Mechanisms of Liver Fibrosis
Acharya, P., Chouhan, K., Weiskirchen, S., & Weiskirchen, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671640 · Cited by 252
“Studies show that at least 50% of the activated MFBs revert to less fibrogenic or quiescent HSCs (Kisseleva et al., 2012; Troeger et al., 2012).”
BackgroundVan De Water, L., Varney, S., & Tomasek, J. J. (2013) · Advances in Wound Care · doi:10.1089/wound.2012.0393 · Cited by 251
Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis
Lagares, D., Santos, A., Grasberger, P. E., Liu, F., Probst, C. K., Rahimi, R. A., Sakai, N., Kuehl, T., Ryan, J., Bhola, P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3765 · Cited by 246
Pericytes at the intersection between tissue regeneration and pathology: Figure 1
Birbrair, A., Zhang, T., Wang, Z.-M., Messi, M. L., Mintz, A., & Delbono, O. (2015) · Clinical Science · doi:10.1042/cs20140278 · Cited by 245
Wu, C.-F., Chiang, W.-C., Lai, C.-F., Chang, F.-C., Chen, Y.-T., Chou, Y.-H., Wu, T.-H., Linn, G. R., Ling, H., Wu, K.-D., et al. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.09.009 · Cited by 245
Tanwar, S., Rhodes, F., Srivastava, A., Trembling, P. M., & Rosenberg, W. M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i2.109 · Cited by 241
Myofibroblasts: Function, Formation, and Scope of Molecular Therapies for Skin Fibrosis
Tai, Y., Woods, E. L., Dally, J., Kong, D., Steadman, R., Moseley, R., & Midgley, A. C. (2021) · Biomolecules · doi:10.3390/biom11081095 · Cited by 240
Duran, A., Hernandez, E. D., Reina-Campos, M., Castilla, E. A., Subramaniam, S., Raghunandan, S., Roberts, L. R., Kisseleva, T., Karin, M., Diaz-Meco, M. T., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.004 · Cited by 239
Self-citationNovel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro
Leite, S. B., Roosens, T., El Taghdouini, A., Mannaerts, I., Smout, A. J., Najimi, M., Sokal, E., Noor, F., Chesne, C., & van Grunsven, L. A. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.026 · Cited by 234
Mechanical control of cardiac myofibroblasts
van Putten, S., Shafieyan, Y., & Hinz, B. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.11.025 · Cited by 234
The Role of Myofibroblasts in Physiological and Pathological Tissue Repair
Schuster, R., Younesi, F., Ezzo, M., & Hinz, B. (2023) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041231 · Cited by 232
Bates, J., Vijayakumar, A., Ghoshal, S., Marchand, B., Yi, S., Kornyeyev, D., Zagorska, A., Hollenback, D., Walker, K., Liu, K., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.037 · Cited by 230
Metabolic Hallmarks of Hepatic Stellate Cells in Liver Fibrosis
Khomich, O., Ivanov, A. V., & Bartosch, B. (2019) · Cells · doi:10.3390/cells9010024 · Cited by 224
“Expression of the fibrogenic genes collagen-α1, α-SMA, TGFβRI, and TIMP1 returned to baseline; however, expression of genes characteristic for quiescent HSCs such adiponectin receptor 1 and the lipid droplet binding factor perilipin 2 was not restored [18].”
BackgroundMitochondrial dysfunction in fibrotic diseases
Li, X., Zhang, W., Cao, Q., Wang, Z., Zhao, M., Xu, L., & Zhuang, Q. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00316-9 · Cited by 224
The balancing act of the liver: tissue regeneration versus fibrosis
Cordero-Espinoza, L., & Huch, M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93562 · Cited by 219
Martin, K., Pritchett, J., Llewellyn, J., Mullan, A. F., Athwal, V. S., Dobie, R., Harvey, E., Zeef, L., Farrow, S., Streuli, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms12502 · Cited by 219
Hyun, J., Wang, S., Kim, J., Rao, K. M., Park, S. Y., Chung, I., Ha, C.-S., Kim, S.-W., Yun, Y. H., & Jung, Y. (2016) · Nature Communications · doi:10.1038/ncomms10993 · Cited by 219
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 218
Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis
Mallat, A., & Lotersztajn, S. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00230.2013 · Cited by 211
“However, reverted HSCs do not reacquire all of the characteristics of quiescent cells, but rather retain an activated intermediate state with enhanced susceptibility to a fibrogenic stimulus (41, 89).”
BackgroundSmoothened is a master regulator of adult liver repair
Michelotti, G. A., Xie, G., Swiderska, M., Choi, S. S., Karaca, G., Krüger, L., Premont, R., Yang, L., Syn, W.-K., Metzger, D., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66904 · Cited by 208
Complex Relationship Between Cardiac Fibroblasts and Cardiomyocytes in Health and Disease
Hall, C., Gehmlich, K., Denning, C., & Pavlovic, D. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019338 · Cited by 205
Liu, X., Xu, J., Rosenthal, S., Zhang, L.-J., McCubbin, R., Meshgin, N., Shang, L., Koyama, Y., Ma, H.-Y., Sharma, S., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.027 · Cited by 205
Self-citationMechanisms of liver fibrosis resolution
Tacke, F., & Trautwein, C. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.039 · Cited by 205
Conway, B. R., O’Sullivan, E. D., Cairns, C., O’Sullivan, J., Simpson, D. J., Salzano, A., Connor, K., Ding, P., Humphries, D., Stewart, K., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020060806 · Cited by 196
The bright side of fibroblasts: molecular signature and regenerative cues in major organs
Gomes, R. N., Manuel, F., & Nascimento, D. S. (2021) · npj Regenerative Medicine · doi:10.1038/s41536-021-00153-z · Cited by 156
Akkız, H., Gieseler, R. K., & Canbay, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147873 · Cited by 191
“Its underlying basic mechanisms are usually investigated in experimental mouse models [3,183–185].”
BackgroundManagement Strategies for Liver Fibrosis
Altamirano-Barrera, A., Barranco-Fragoso, B., & Méndez-Sánchez, N. (2017) · Annals of Hepatology · doi:10.5604/16652681.1226814 · Cited by 191
Metadata
- Authors
- Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., Evans, S. M., Dillmann, W., Glass, C. K., & Brenner, D. A.
- Affiliations
- Department of Medicine,
- Universitätsklinikum Aachen (DE)
- Department of Cellular and Molecular Medicine,
- School of Pharmacy, University of California, San Diego, CA 92093;
- University of Southern California (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2012-05-07
- Volume
- 109
- Issue
- 24
- Pages
- 9448-9453
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3386114
- OpenAlex
- W2075290880
- Cited by
- 805
- References
- 27
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 61 · 2023: 59 · 2022: 53 · 2021: 62 · 2020: 64 · 2019: 52 · 2018: 53 · 2017: 61 · 2016: 64 · 2015: 73 · 2014: 63 · 2013: 42 · 2012: 13
- FWCI
- 38.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM041804)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- myofibroblasts, hepatic stellate cells, liver fibrosis, fibrosis regression, apoptosis, anti-apoptotic genes, carbon tetrachloride, alcohol-induced liver injury, fibrogenic gene expression
- MeSH terms
- Animals, Liver Cirrhosis, Phenotype, Tamoxifen, Adoptive Transfer, Collagen Type I, Mice, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.